655 related articles for article (PubMed ID: 32326412)
1. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.
Kovar H; Bierbaumer L; Radic-Sarikas B
Cells; 2020 Apr; 9(4):. PubMed ID: 32326412
[TBL] [Abstract][Full Text] [Related]
2. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
3. Snail/Slug-YAP/TAZ complexes cooperatively regulate mesenchymal stem cell function and bone formation.
Tang Y; Weiss SJ
Cell Cycle; 2017 Mar; 16(5):399-405. PubMed ID: 28112996
[TBL] [Abstract][Full Text] [Related]
4. An overview of signaling pathways regulating YAP/TAZ activity.
Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
7. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis.
Kim J; Kwon H; Shin YK; Song G; Lee T; Kim Y; Jeong W; Lee U; Zhang X; Nam G; Jeung HC; Kim W; Jho EH
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13529-13540. PubMed ID: 32482852
[TBL] [Abstract][Full Text] [Related]
8. Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.
Komatsu N; Kajiya M; Motoike S; Takewaki M; Horikoshi S; Iwata T; Ouhara K; Takeda K; Matsuda S; Fujita T; Kurihara H
Stem Cell Res Ther; 2018 Dec; 9(1):342. PubMed ID: 30526677
[TBL] [Abstract][Full Text] [Related]
9. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function.
Sun C; De Mello V; Mohamed A; Ortuste Quiroga HP; Garcia-Munoz A; Al Bloshi A; Tremblay AM; von Kriegsheim A; Collie-Duguid E; Vargesson N; Matallanas D; Wackerhage H; Zammit PS
Stem Cells; 2017 Aug; 35(8):1958-1972. PubMed ID: 28589555
[TBL] [Abstract][Full Text] [Related]
10. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
12. YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells.
Bierbaumer L; Katschnig AM; Radic-Sarikas B; Kauer MO; Petro JA; Högler S; Gurnhofer E; Pedot G; Schäfer BW; Schwentner R; Mühlbacher K; Kromp F; Aryee DNT; Kenner L; Uren A; Kovar H
Oncogenesis; 2021 Jan; 10(1):2. PubMed ID: 33419969
[TBL] [Abstract][Full Text] [Related]
13. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.
Molina ER; Chim LK; Salazar MC; Mehta SM; Menegaz BA; Lamhamedi-Cherradi SE; Satish T; Mohiuddin S; McCall D; Zaske AM; Cuglievan B; Lazar AJ; Scott DW; Grande-Allen JK; Ludwig JA; Mikos AG
Acta Biomater; 2019 Dec; 100():38-51. PubMed ID: 31542501
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone.
Isfort I; Elges S; Cyra M; Berthold R; Renner M; Mechtersheimer G; Åman P; Larsson O; Ratner N; Hafner S; Simmet T; Schliemann C; Rossig C; Dirksen U; Grünewald I; Wardelmann E; Huss S; Hartmann W; Trautmann M
Sci Rep; 2019 Dec; 9(1):19704. PubMed ID: 31873172
[TBL] [Abstract][Full Text] [Related]
15. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
17. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
18. Gone Caving: Roles of the Transcriptional Regulators YAP and TAZ in Skeletal Development.
Kegelman CD; Collins JM; Nijsure MP; Eastburn EA; Boerckel JD
Curr Osteoporos Rep; 2020 Oct; 18(5):526-540. PubMed ID: 32712794
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
[TBL] [Abstract][Full Text] [Related]
20. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis.
Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY
Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
